Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' Candidate Tuberculosis Vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) | BIOLOGICAL | Intramuscular injection, 2 doses at 0, 1 month |
Inclusion Criteria: * Subjects who the Investigator believes that they can and will comply with the requirements of the protocol. * A male or female between, and including, 21 and 40 years of age at the time of the first vaccination. * Written informed consent obtained from the subject prior to any...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Ganfeborole |
GSK Biologicals' Candidate Tuberculosis Vaccine is an investigational vaccine developed by GSK plc for the prevention of tuberculosis (TB). It is a Phase 2 candidate in the infectious disease therapeutic area. It has been studied in healthy adult volunteers in a TB-endemic region and is not an approved product.
It is being developed for tuberculosis (TB), the infectious disease caused by Mycobacterium tuberculosis. The vaccine is intended for use in healthy adults, including those living in TB-endemic regions. Its development remains at the Phase 2 stage, so it is not available as a licensed vaccine for TB prevention.
GSK Biologicals' Candidate Tuberculosis Vaccine is developed by GSK plc, which trades under the ticker GSK. GSK Biologicals is the vaccines unit of the company. The candidate carries the internal identifier 692342 and is referred to as Formulation 1 in its trial documentation.
GSK Biologicals' Candidate Tuberculosis Vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA or any other regulator. One Phase 2 trial has been completed, and no trials of this candidate are currently listed as active.
The candidate has been evaluated in one completed Phase 2 trial, NCT00600782, titled Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region. The study enrolled 45 healthy adults aged 21 years and older in South Africa and was an uncontrolled, non-randomized trial.